why are there so many glp 1 drugs Employer FAQs on the Rise of GLP-1 for Weight Loss and the Workplace Impact | Fisher Phillips GLP-1 Drugs and Eating Disorders:

Cardiovasc Ther 2013;31:238249

NAS, NAFLD activity score

Even if not every person with obesity should be on GLP-1 drugs, theres still a huge gap

This includes hepatic steatosis, where 5% or more hepatocytes have macrovesicular steatosis in the absence of other causes of macrovascular steatosis in individuals who drink little or no alcohol, which is defined as less than 20 g/day for women and less than 30 g/day for men

However, translation of these in vitro effects into in vivo outcomes has not yet been examined further [95]

Cardiovascular outcome studies were not required for the approval of pramlintide, and the available preclinical data are insufficient to predict whether amylin agonism will impact cardiovascular pathophysiology in susceptible individuals